Open AccessApremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study
Author(s) -
Gülen Hatemi,
Melike Melikoğlu,
Recep Tunç,
Cengiz Korkmaz,
Banu Öztürk,
Cem Mat,
Peter A. Merkel,
Kenneth Calamia,
Ziqi Liu,
Lilia Pineda,
Randall M. Stevens,
Hasan Yazıcı,
Yusuf Yazıcı
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1408684
Subject(s) - apremilast , medicine , placebo , dermatology , alternative medicine , psoriasis , pathology , psoriatic arthritis
Oral ulcers, the hallmark of Behçet's syndrome, can be resistant to conventional treatment; therefore, alternative agents are needed. Apremilast is an oral phosphodiesterase-4 inhibitor that modulates several inflammatory pathways.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom